PUB73 Antibody
Description
Potential Contextual Associations
The designation "PUB73" appears in Source as part of a plasmid construct (pUB73pre) used in Trypanosoma brucei research to study glycosylphosphatidylinositol (GPI)-anchored proteins. This plasmid was engineered to express a transmembrane variant of the VSG117 protein, but no antibody named "PUB73" is described in this context. The study utilized anti-VSG117 antibodies for immunofluorescence and Western blotting .
p73 Antibodies in Cancer Research
The search results highlight p73 antibodies, which target the p73 protein—a member of the p53 tumor suppressor family. Key findings include:
Clinical Relevance
-
p73 antibodies are detected in 14.9% of cancer patients (vs. 4% in healthy controls) .
-
These antibodies are associated with p73 protein accumulation in tumors, suggesting a tumor-specific immune response .
-
Epitope mapping shows p73 antibodies primarily target the central region of the p73 protein, unlike p53 antibodies, which bind terminal regions .
Anti-CD73 Antibodies in Immunotherapy
While unrelated to "PUB73," CD73-targeting antibodies represent a critical area of cancer immunotherapy research:
Functional Mechanisms
-
CD73 converts extracellular AMP to adenosine, suppressing immune responses. Blocking CD73 enhances antitumor activity .
-
Mupadolimab: An anti-CD73 antibody that activates B cells, enhances antigen-specific antibody production, and redistributes B cells to lymphoid tissues in cancer patients .
-
Biparatopic CD73 antibodies (e.g., TB19/TC29) inhibit enzymatic activity at subnanomolar EC50 values, outperforming monospecific antibodies .
Clinical Trials
-
Mupadolimab demonstrated safety in a Phase 1 trial (NCT03454451) and induced transient B cell depletion with minor tumor regression .
Technical Insights from Antibody Studies
Product Specs
**Constituents:** 50% Glycerol, 0.01M PBS, pH 7.4
